Estimating Glomerular Filtration Rate in Kidney Transplant Recipients
NCT ID: NCT05229939
Last Updated: 2022-08-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
11412 participants
OBSERVATIONAL
2000-01-01
2021-01-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Trajectories of Glomerular Filtration Rate and Progression to End Stage Renal Disease After Kidney Transplantation
NCT04226859
Measuring Kidney Function in Kidney Transplantation
NCT00212979
Use of Predigraft in Kidney Transplant Patients
NCT04969757
Prospective Study of Urinary Markers of Fibrosis in Kidney Transplants
NCT01982903
Renal Function Prediction in Living Donor Transplant Using Baseline Data
NCT06728995
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The project therefore aims to:
1. Develop new kidney-recipient-specific (KRS) GFR equations and compare their performances with the standard GFR equations
2. Investigate whether the use of race increasers the performances of the new kidney-recipient-specific (KRS) GFR equations
3. Evaluate the effects of the new equations on the chronic kidney disease (CKD) prevalence and GFR stage
This study will provide us with data of kidney transplant patients that may allow the development of a new KRS GFR equation.
A new KRS GFR equation that presents with increased performances, as compared to current GFR equations, will improve the GFR calculation in kidney recipients, and therefore improve clinical decisions and the long-term kidney allograft management. Decisions regarding the return to dialysis or placement on the transplant waiting list will be taken with more accuracy and therefore potentially improve the financial allocation of kidney transplantation for the society.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Development cohort
kidney transplant recipients in 3 centres in France: Necker, Saint-Louis and Toulouse hospitals
No intervention
Kidney recipients aged over 18 and of all sexes recruited from 2000 who have mGFR follow-up and clinical, biological, and immunological data
Validation cohort 1
kidney transplant recipients from Montpellier Hospital, France
No intervention
Kidney recipients aged over 18 and of all sexes recruited from 2000 who have mGFR follow-up and clinical, biological, and immunological data
Validation cohort 2
kidney transplant recipients from Lyon Hospital, France
No intervention
Kidney recipients aged over 18 and of all sexes recruited from 2000 who have mGFR follow-up and clinical, biological, and immunological data
Validation cohort 3
kidney transplant recipients from Tenon Hospital, France
No intervention
Kidney recipients aged over 18 and of all sexes recruited from 2000 who have mGFR follow-up and clinical, biological, and immunological data
Validation cohort 4
kidney transplant recipients from Saint-Etienne Hospital, France
No intervention
Kidney recipients aged over 18 and of all sexes recruited from 2000 who have mGFR follow-up and clinical, biological, and immunological data
Validation cohort 5
kidney transplant recipients from Mayo Clinic Hospital, USA
No intervention
Kidney recipients aged over 18 and of all sexes recruited from 2000 who have mGFR follow-up and clinical, biological, and immunological data
Validation cohort 6
kidney transplant recipients from Bergamo hospital, Italy
No intervention
Kidney recipients aged over 18 and of all sexes recruited from 2000 who have mGFR follow-up and clinical, biological, and immunological data
Validation cohort 7
kidney transplant recipients from Zagreb hospital, Croatia
No intervention
Kidney recipients aged over 18 and of all sexes recruited from 2000 who have mGFR follow-up and clinical, biological, and immunological data
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
No intervention
Kidney recipients aged over 18 and of all sexes recruited from 2000 who have mGFR follow-up and clinical, biological, and immunological data
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Men or women over 18 years of age.
* Written informed consent at the time of transplantation for the center database.
Exclusion Criteria
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Paris Translational Research Center for Organ Transplantation
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Alexandre Loupy, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Paris Translational Research Center for Organ Transplantation
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
William J. von Liebig Centre for Transplantation and Clinical Regeneration, Mayo Clinic
Rochester, Minnesota, United States
Department of Nephrology, Arterial Hypertension, Dialysis and Transplantation, University Hospital Centre Zagreb, School of Medicine, University of Zagreb
Zagreb, , Croatia
Department of Transplantation, Nephrology and Clinical Immunology, Hospices Civils de Lyon
Lyon, , France
Department of Nephrology, Centre Hospitalier Universitaire, Montpellier
Montpellier, , France
Kidney Transplant Department, Necker Hospital, Assistance Publique - Hôpitaux de Paris
Paris, , France
Kidney Transplant Department, Saint-Louis Hospital, Assistance Publique - Hôpitaux de Paris
Paris, , France
Kidney Transplant Department, Tenon Hospital, Assistance Publique - Hôpitaux de Paris
Paris, , France
Nephrology, Dialysis and Renal Transplantation Department, Hôpital Nord, CHU de Saint-Etienne, Jean Monnet University, Université de Lyon
Saint-Etienne, , France
Department of Nephrology and Organ Transplantation, CHU Rangueil
Toulouse, , France
Istituto di Ricerche Farmacologiche Mario Negri IRCCS
Bergamo, , Italy
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Raynaud M, Al-Awadhi S, Juric I, Divard G, Lombardi Y, Basic-Jukic N, Aubert O, Dubourg L, Masson I, Mariat C, Prie D, Pernin V, Le Quintrec M, Larson TS, Stegall MD, Bikbov B, Ruggenenti P, Mesnard L, Ibrahim HN, Nielsen MB, Matas AJ, Nankivell BJ, Benjamens S, Pol RA, Bakker SJL, Jouven X, Legendre C, Kamar N, Smith BH, Wadei HM, Durrbach A, Vincenti F, Remuzzi G, Lefaucheur C, Bentall AJ, Loupy A. Race-free estimated glomerular filtration rate equation in kidney transplant recipients: development and validation study. BMJ. 2023 May 31;381:e073654. doi: 10.1136/bmj-2022-073654.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
KRSeGFR2021
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.